Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Coherus BioSciences, Inc.”

73 pharma patents match "Coherus BioSciences, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 73
Index total 30,257
Page 2 / 4

Quick answer

This filtered view shows 73 pharmaceutical patents matching "Coherus BioSciences, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

73 results for “Coherus BioSciences, Inc.” · 30,257 patents in full index Clear search

  1. US 10786566

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 29, 2020 · Expires Sep 24, 2040

    granted

  2. US 10780163

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 22, 2020 · Expires Sep 17, 2040

    granted

  3. US 10772963

    Etanercept formulations stabilized with xylitol

    Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  4. US 10772865

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  5. US 10772959

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  6. US 10772960

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted

  7. US 10722579

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  8. US 10716852

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  9. US 10716854

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  10. US 10716853

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  11. US 10688183

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  12. US 10555929

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Coherus BioSciences, Inc. · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted

  13. US 10493151

    Etanercept formulations stabilized with sodium chloride

    Coherus BioSciences, Inc. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted

  14. US 10485869

    Etanercept formulations stabilized with meglumine

    Coherus BioSciences, Inc. · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted

  15. US 10376588

    Etanercept formulations stabilized with combinations of sugars and polyols

    Coherus BioSciences, Inc. · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted

  16. US 10293049

    Etanercept formulations stabilized with amino acids

    Coherus BioSciences, Inc. · Granted May 21, 2019 · Expires May 16, 2039

    granted

  17. US 10286072

    Methods of manufacturing stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted

  18. US 10286071

    Syringe containing stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted

  19. US 10213508

    Etanercept formulations stabilized with xylitol

    Coherus BioSciences, Inc. · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted

  20. US 10207000

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted

  21. US 10195275

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted

  22. US 10159733

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  23. US 10159732

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  24. US 10155039

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Dec 18, 2018 · Expires Dec 13, 2038

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.